Introduction
Multiple myeloma, multiple myeloma, MM
MULTIPLE MYELOMA, HEMATOLOGICAL MALIGNANCIES, MULTIPLE MYELOMA
Multiple myeloma (MM) is one of the most frequent hematological malignancies. The introduction of two types of cornerstone new drugs, proteasome inhibitors (PIs) represented by bortezomib and immunomodulatory drugs (IMIDs) lenalidomide, has greatly improved the outcome of multiple myeloma patients. Based on the different and synergistic pharmacological mechanisms of lenalidomide and bortezomib, the phase 3 clinical trial SWOG S0777 confirmed that the combination of bortezomib and lenalidomide (VRd) would bring deeper responses and a higher response rate and improve the prognosis [It is unknown whether sequential administration of bortezomib-based triplet regimens without lenalidomide (PXD) as initial therapy and followed by Rd as continuous treatment has similar efficacy to VRd. Mateos MV et al